The off target effects of small molecule inhibitors of AXL coupled with the high binding affinity of Gas6 for its receptor AXL led to the development of a soluble AXL decoy receptor with increased GAS6 binding affinity and specific AXL inhibition in a variety of cancers, including ovarian, renal, breast and pancreatic cancers [15,16,23]. The gene discussed is AXL; the disease is pancreatic neoplasm.